Operating Income - CASI Pharmaceuticals Inc (NASDAQ:CASI) - Alpha Spread
C

CASI Pharmaceuticals Inc
NASDAQ:CASI

Watchlist Manager
CASI Pharmaceuticals Inc
NASDAQ:CASI
Watchlist
Price: 6.54 USD -3.25% Market Closed
Market Cap: 87.6m USD
Have any thoughts about
CASI Pharmaceuticals Inc?
Write Note

CASI Pharmaceuticals Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CASI Pharmaceuticals Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
C
CASI Pharmaceuticals Inc
NASDAQ:CASI
Operating Income
-$25.3m
CAGR 3-Years
9%
CAGR 5-Years
1%
CAGR 10-Years
-16%
Abbvie Inc
NYSE:ABBV
Operating Income
$16B
CAGR 3-Years
-1%
CAGR 5-Years
5%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.3B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.2B
CAGR 3-Years
23%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-14%
CAGR 5-Years
14%
CAGR 10-Years
17%

See Also

What is CASI Pharmaceuticals Inc's Operating Income?
Operating Income
-25.3m USD

Based on the financial report for Dec 31, 2023, CASI Pharmaceuticals Inc's Operating Income amounts to -25.3m USD.

What is CASI Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-16%

Over the last year, the Operating Income growth was 5%. The average annual Operating Income growth rates for CASI Pharmaceuticals Inc have been 9% over the past three years , 1% over the past five years , and -16% over the past ten years .

Back to Top